Literature DB >> 32110656

Symptoms of Primary Hyperparathyroidism in Men and Women: The Same but Different?

Theresia Weber1, Andreas Hillenbrand2, Simon Peth1, Rainer Hummel1.   

Abstract

INTRODUCTION AND
OBJECTIVE: Typical symptoms for primary hyperparathyroidism (pHPT) include osteoporosis, bone or joint pain, and nephrolithiasis, as well as fatigue, depression, gastritis, and cardiovascular disease. The female:male ratio was 3:1. The aim of this retrospective study was to evaluate the possible influence of gender-specific aspects of these symptoms.
METHODS: From February 2018 to November 2019, parathyroid surgery was performed in 125 patients with pHPT (age: 23-83 years); 95 (76%) were female, and 30 (24%) were male. Preoperatively, a standardized medical history including 7 typical symptoms of pHPT was used for routine clinical documentation according to the StuDoQ Thyroid and Parathyroid Registry.
RESULTS: For both groups (mean age: 60.4 years for females and 60.2 years for males), no sex differences were found in serum calcium or parathyroid hormone levels. For females, there was a tendency towards smaller hyperfunctioning parathyroid glands (16.8 vs. 20.5 mm) with less weight (1.14 vs. 1.52 g) and multiglandular disease. Nephrolithiasis was significantly more frequent in men than in women (36.7 vs. 16.8%, respectively; p = 0.036), but the difference in hypertension was not significant (60% in men vs. 47.4% in women, p = 0.230). Women reported significantly more often bone and joint pain (44.2% in women vs. 20% in men, p = 0.053) and depressive episodes (32.6% in women vs. 10% in men, p = 0.016).
CONCLUSION: 91.2% of patients transferred for parathyroidectomy described typical symptoms of pHPT. However, an unexpected high gender difference was found following the analysis of symptoms documented in the StuDoQ Registry.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Gender; Primary hyperparathyroidism; Symptoms

Year:  2020        PMID: 32110656      PMCID: PMC7036559          DOI: 10.1159/000505497

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  18 in total

1.  Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000.

Authors:  A Hesse; E Brändle; D Wilbert; K-U Köhrmann; P Alken
Journal:  Eur Urol       Date:  2003-12       Impact factor: 20.096

2.  Prevalence and Risk of Vertebral Fractures in Primary Hyperparathyroidism: A Nested Case-Control Study.

Authors:  Henriette Ejlsmark-Svensson; Lise Sofie Bislev; Siv Lajlev; Torben Harsløf; Lars Rolighed; Tanja Sikjaer; Lars Rejnmark
Journal:  J Bone Miner Res       Date:  2018-06-07       Impact factor: 6.741

3.  Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism.

Authors:  D Han; S Trooskin; X Wang
Journal:  J Endocrinol Invest       Date:  2011-07-12       Impact factor: 4.256

4.  The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism.

Authors:  Sanziana A Roman; Julie Ann Sosa; Robert H Pietrzak; Peter J Snyder; Daniel C Thomas; Robert Udelsman; Linda Mayes
Journal:  Ann Surg       Date:  2011-01       Impact factor: 12.969

5.  The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.

Authors:  Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty
Journal:  JAMA Surg       Date:  2016-10-01       Impact factor: 14.766

6.  Sex Difference in the Clinical Presentation of Primary Hyperparathyroidism: Influence of Menopausal Status.

Authors:  Elena Castellano; Roberto Attanasio; Alberto Boriano; Micaela Pellegrino; Francesca Garino; Laura Gianotti; Giorgio Borretta
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

7.  Patient-based surgical outcome tool demonstrating alleviation of symptoms following parathyroidectomy in patients with primary hyperparathyroidism.

Authors:  Janice L Pasieka; Louise L Parsons; Michael J Demeure; Stuart Wilson; Peter Malycha; Jean Jones; Beth Krzywda
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

8.  Parathyroidectomy, elevated depression scores, and suicidal ideation in patients with primary hyperparathyroidism: results of a prospective multicenter study.

Authors:  Theresia Weber; Julia Eberle; Ursula Messelhäuser; Leif Schiffmann; Christoph Nies; Jochen Schabram; Andreas Zielke; Katharina Holzer; Edit Rottler; Doris Henne-Bruns; Monika Keller; Jörn von Wietersheim
Journal:  JAMA Surg       Date:  2013-02       Impact factor: 14.766

Review 9.  Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Authors:  A A Khan; D A Hanley; R Rizzoli; J Bollerslev; J E M Young; L Rejnmark; R Thakker; P D'Amour; T Paul; S Van Uum; M Zakaria Shrayyef; D Goltzman; S Kaiser; N E Cusano; R Bouillon; L Mosekilde; A W Kung; S D Rao; S K Bhadada; B L Clarke; J Liu; Q Duh; E Michael Lewiecki; F Bandeira; R Eastell; C Marcocci; S J Silverberg; R Udelsman; K Shawn Davison; J T Potts; M L Brandi; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-09-09       Impact factor: 4.507

10.  Gender differences in bone mineral density in patients with sporadic primary hyperparathyroidism.

Authors:  Danica M Vodopivec; Angelica M Silva; Dinamarie C Garcia-Banigan; Ioannis Christakis; Ashley Stewart; Kelly Schwarz; Caroline S Hussey; Roland Bassett; Mimi I Hu; Nancy D Perrier
Journal:  Endocrinol Diabetes Metab       Date:  2018-09-04
View more
  1 in total

1.  Primary hyperparathyroidism in Saudi Arabia revisited: a multi-centre observational study.

Authors:  Yousef Al-Saleh; Abdullah AlSohaim; Reem AlAmoudi; Ali AlQarni; Raed Alenezi; Layla Mahdi; Hend Alzanbaqi; Samah M Nawar; Hibah AlHarbi; Abdulrhman ALMulla; Maryam Al Qahtani; Salih Bin Salih; Faisal Al Anazi; Najla Saleh; Seham Saleh; Ali AlAklabi; Shaun Sabico; Nasser M Al-Daghri
Journal:  BMC Endocr Disord       Date:  2022-06-09       Impact factor: 3.263

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.